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Abstract
Background: Type 2 diabetes mellitus is a chronic disease that has been increasing in prevalence in the
United States every year. Diabetes is associated with numerous physical health complications, most notably
the development of cardiovascular disease. In addition, the financial burden imposed by diabetes is great and
includes medical costs and lost work time. Most patients with diabetes take prescription oral anti-diabetic
medications (OADs) but still do not have adequate glycemic control. When adequate glycemic control is not
achieved with these medications, injectable insulin is then required; it is understandable that patients object to
this type of invasive treatment and would prefer to remain on oral therapies. Over-the-counter dietary
supplements, specifically chromium picolinate and biotin, have been studied for their efficacy as glycemic
control agents; the purpose of this metasynthesis was to review existing literature pertaining to concurrent use
of both chromium picolinate and biotin supplements as adjunct therapy to prescription OADs to determine if
improved glycemic control is achieved in patients with type 2 diabetes mellitus.
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, and Web of Science using
the keywords: diabetes, chromium picolinate and biotin. Relevant articles were assessed for quality using the
GRADE system. A search on the NIH clinical trials site revealed there are no trials currently registered relating
to the concomitant use of chromium picolinate and biotin in patients with type 2 diabetes mellitus.
Results: Ninety-six articles were reviewed for relevancy; two met inclusion criteria and were included in this
systematic review. Both studies included were randomized, double blind, placebo-controlled trials that found
a statistically significant improvement in glycemic control with dual chromium picolinate and biotin
treatment.
Conclusion: Chromium picolinate and biotin appear to modestly improve glycemic control. Chromium
picolinate and biotin are safe, over-the-counter supplements; due to evidence obtained from prior animal
studies, the lack of significant adverse drug reactions and modest-to-substantial blood-glucose reducing
effects, chromium picolinate and biotin supplementation as adjunct therapy to prescription OADs may be
clinically justified.
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Abstract   
 
Background: Type 2 diabetes mellitus is a chronic disease that has been increasing in 
prevalence in the United States every year. Diabetes is associated with numerous physical 
health complications, most notably the development of cardiovascular disease. In addition, 
the financial burden imposed by diabetes is great and includes medical costs and lost work 
time. Most patients with diabetes take prescription oral anti-diabetic medications (OADs) but 
still do not have adequate glycemic control. When adequate glycemic control is not achieved 
with these medications, injectable insulin is then required; it is understandable that patients 
object to this type of invasive treatment and would prefer to remain on oral therapies. Over-
the-counter dietary supplements, specifically chromium picolinate and biotin, have been 
studied for their efficacy as glycemic control agents; the purpose of this metasynthesis was to 
review existing literature pertaining to concurrent use of both chromium picolinate and biotin 
supplements as adjunct therapy to prescription OADs to determine if improved glycemic 
control is achieved in patients with type 2 diabetes mellitus. 
 
Methods: An exhaustive search was conducted using Medline-OVID, CINAHL, and Web of 
Science using the keywords: diabetes, chromium picolinate and biotin. Relevant articles were 
assessed for quality using the GRADE system. A search on the NIH clinical trials site 
revealed there are no trials currently registered relating to the concomitant use of chromium 
picolinate and biotin in patients with type 2 diabetes mellitus.  
 
Results: Ninety-six articles were reviewed for relevancy; two met inclusion criteria and were 
included in this systematic review. Both studies included were randomized, double blind, 
placebo-controlled trials that found a statistically significant improvement in glycemic 
control with dual chromium picolinate and biotin treatment.  
 
Conclusion:  Chromium picolinate and biotin appear to modestly improve glycemic control. 
Chromium picolinate and biotin are safe, over-the-counter supplements; due to evidence 
obtained from prior animal studies, the lack of significant adverse drug reactions and modest-
to-substantial blood-glucose reducing effects, chromium picolinate and biotin 
supplementation as adjunct therapy to prescription OADs may be clinically justified.  
 
Keywords: Type 2 diabetes mellitus, chromium picolinate, biotin, glycemic control, human 
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Chromium Picolinate and Biotin Supplementation May 
Improve Glycemic Control in Patients with Type 2 
Diabetes Mellitus 
 
 
BACKGROUND 
The prevalence of diabetes, especially type 2 diabetes mellitus (DMT2) in the United 
States has been increasing every year.1 As of 2011, 8.5%, or almost 20 million of U.S. adults 
have physician-diagnosed diabetes, with another estimated 11 million adults with 
undiagnosed diabetes. Of this combined approximate 31 million, 90%-95% have DMT2.2,3  
The physical complications of diabetes are vast and include, but are not limited to, 
significant cardiac, hepatic, and renal diseases.4-11 In addition to the physical health 
complications, diabetes takes a substantial economic toll.  In 2012, total economic burden of 
diabetes including medical costs, disability, work loss and premature death was estimated at 
$245 billion.12 The costs of health complications alone attributable to diabetes is on average 
$47 240 per patient over 30 years.13  
Both health and financial consequences can be reduced if patients with diabetes 
obtain adequate glycemic control. Glycemic control can be obtained through weight loss and 
careful attention to diet for many,14 but the majority of overweight or obese people are either 
unsuccessful complying with a weight loss regimen or are unsuccessful at maintaining any 
weight lost.15,16 As a result, most patients with DMT2 take prescription oral anti-diabetic 
medications (OADs). Approximately 85.6% of patients with diabetes take OADs, insulin, or 
both.12 The most frequently used medications reduce glycated hemoglobin (HbA1c) on 
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average between 1%-2% and are metformin, sulfonylureas, and thiazolidinediones, but they 
come with numerous adverse drug reactions (ADRs) including diarrhea, lactic acidosis, 
weight gain, hypoglycemic events, hepatotoxicity, and congestive heart failure.17-20  
Chromium deficiency has been shown to cause insulin resistance and diabetes,21 so it 
has been postulated that chromium supplementation can reverse these conditions.22,23 
Chromium supplementation has been studied as a blood-glucose lowering agent in both 
animal and human models with mixed results.23,24 One study23 found supplemental chromium 
had little effect lowering blood glucose on the entire study cohort as a whole, but found a 
significant lowering of HbA1c and increased insulin sensitivity compared to baseline in a 
cohort subset considered “responders”. Another study25 demonstrated a decreased 
requirement for exogenous insulin with chromium administration.   
In addition to chromium, biotin treatment has been shown to improve insulin 
resistance and impaired glucose tolerance as well as decrease blood glucose in several animal 
studies.26-30 In one study,27 genetically diabetic mice were given various levels of biotin; after 
10 weeks the mice demonstrated lowered post-prandial glucose levels and improved insulin 
resistance.  In three other studies involving diabetic rats, biotin was shown to prevent insulin 
resistance in skeletal muscle28 and to improve impaired glucose tolerance.29,30  More 
importantly, in a human study, poorly-controlled diabetics showed a significantly improved 
fasting glucose after receiving biotin for one month.31 Results of these studies have lead 
researchers to consider dual treatment with chromium and biotin as adjunct therapy to 
prescription OADs for glycemic control improvement in patients with DMT2. 
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METHODS 
  An exhaustive search of available medical literature was conducted using Medline-
OVID, CINAHL, and Web of Science using the keywords: diabetes, chromium picolinate 
and biotin. The bibliographies of the articles were further searched for relevant sources. 
Articles with primary data evaluating the effectiveness of dual therapy with CrPic and biotin 
for glycemic control improvement in people with DMT2 were included. Relevant articles 
were assessed for quality using the Grading of Recommendations, Assessment, Development 
and Evaluation (GRADE) system.32 A search on the NIH clinical trials site revealed no 
currently registered trials relating to the use of CrPic combined with biotin in patients with 
DMT2. 
RESULTS 
  The initial result of the search yielded 98 articles for review; 8 from Medline-OVID, 
64 from CINAHL and 26 from Web of Science. After screening relevant articles for 
randomized controlled trials, adult patients with DMT2, human subjects and English 
language studies, a total of two articles met inclusion criteria.33,34 Refer to Tables 1 and 2 for 
the GRADE evaluation and summary of results. 
Singer et al study 
This is a randomized, double blind, placebo-controlled trial33 which looked at the 
effect of oral CrPic and biotin at improving glycemic control in overweight patients with 
uncontrolled, treated DMT2.33   
  Glycemic control was measured via plasma fructosamine, insulin and fasting glucose 
levels, area under curve for glucose (AUCg) and oral glucose tolerance test (OGTT) 
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measured at 30, 60, 90 and 120 minutes. Secondary endpoints were effects on total 
cholesterol as well as the cholesterol fractions HDL, LDL, VLDL, ApoA, and ApoB, 
triglycerides and triglyceride:HDL ratio. The trial enrolled 43 subjects at a single study site 
in the United States.33   
Eligibility criteria consisted of patients who were overweight or obese classified with 
a body mass index (BMI)  ≥25 to ≤35 kg/m2; between the ages of 18 and 65; a diagnosis of 
DMT2 for ≥1 year; poorly-controlled (HbA1c ≥7.0%); persistent impaired glucose control 
(2-h glucose >200 mg/dL); and stable on OADs prior to study entry. OADs allowed were 
metformin, sulfonylureas, and thiazolidinediones, but the amount and duration of OADs were 
not controlled for in the study.  Exclusion criteria consisted of patients who were currently on 
or required insulin treatment.33   
Subjects were assigned 1:1 to either a treatment group in which they received 600 µg 
Cr3+ in the form of CrPic and 2 mg biotin, or a placebo group, with a study length of 30 days.  
CrPic and biotin were administered as a single capsule manufactured under the name 
Diachrome® by Nutrition 21, Inc., Purchase, NY. Although the study states it was a 
randomized, double-blind trial it does not give details pertaining to how randomization or 
blinding occurred.33 
Both the treatment group and placebo group were balanced at the beginning of the 
study with respect to demographics, ie, age, sex, race, weight, height, BMI and blood 
pressure (BP), as well as baseline HbA1c (p= 0.1430 to 0.9787). Of the 43 randomized 
patients at the study beginning, seven (16.3%) were either lost to follow-up or excluded for 
protocol violations; one patient was lost from the treatment group and six lost from the 
placebo group. Data were collected on 36 patients considered eligible for analysis after these 
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losses; 20 patients were assigned to the treatment group and 16 patients were assigned to the 
placebo group.33   
Data were recorded as mean values ± SD (see Table 2). Treatment with CrPic and 
biotin significantly reduced fructosamine by 23.0 ± 56 mg/dL (p= 0.3698), as compared to 
placebo which increased by 12.9 ± 33 mg/dL (p= 0.5980); the comparison of the mean 
changes between treatment and placebo was p= 0.0263. Fasting glucose in the treatment 
group increased by 7.45 ± 65 mg/dL (p= 0.6597) as compared to placebo which increased by 
50.19 ± 62 mg/dL (p= 0.0580); treatment vs. placebo was p= 0.0525. Insulin resulted in no 
significant change in either the treatment or placebo groups. AUCg reduced in the treatment 
group by 4701.8 ± 8959 min • mg/dL (p= 0.0441) but increased in the placebo group by 
1649 ± 7013 min • mg/dL (p= 0.5702); treatment vs. placebo was p= 0.0264. OGTT at 30, 
60, 90 and 120 minute intervals all decreased in the treatment group but the changes were not 
considered statistically significant according to p-values.33   
Based on the statistical significance of decrease in fructosamine and AUCg levels vs. 
placebo and the lack of hypoglycemic events or serious ADRs in this study, the authors of 
this study recommended the use of CrPic and biotin supplements to enhance glycemic 
control.33 
Albarracin et al study  
  This randomized, double blind, placebo-controlled trial34 examined the effect of oral 
CrPic and biotin at improving glycemic control in overweight patients with uncontrolled, 
treated DMT2. Glycemic control was measured via serum HbA1c and fasting insulin and 
glucose levels. Secondary endpoints were effects on total cholesterol as well as the 
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cholesterol fractions HDL, LDL, and VLDL, triglycerides, and triglyceride:HDL ratio. The 
trial enrolled 447 subjects from 17 sites in the United States.34  
Eligibility criteria consisted of patients who were overweight or obese (BMI ≥25 to 
<35 kg/m2); between the ages of 18 and 70; a diagnosis of DMT2 according to ADA criteria 
for ≥1 year; poorly-controlled (HbA1c ≥7.0%); stable on OADs for ≥60 days prior to study 
entry; and fasting triglyceride level ≤400 mg/dL. Type, amount, and duration of OADs were 
not controlled for in the study. Exclusion criteria was extensive and consisted of the 
following: diagnosis of type 1 diabetes mellitus; hypoglycemic events requiring emergency 
transport ≤12 months; supplementation with CrPic within 90 days and/or any other form of 
chromium ≥120 µg/d within 30 days; daily insulin usage or rescue insulin usage >1 time per 
week; an incidence of DKA ≤12 months; creatinine, AST or ALT ≥2.0 x ULN; total bilirubin 
≥1.5 x ULN; cardiovascular conditions requiring hospitalization ≤12 months; history of 
CVA, PE or unresolved DVT; uncontrolled high BP ≥160 mmHg systolic or ≥90 mmHg 
diastolic (seated); serious immunosuppressive disorder or current immunosuppressive 
therapy; disorders of the liver, thyroid, or kidneys or other disorders known to affect glucose 
or lipid metabolism; alcoholism or substance abuse; mental health issues that would prevent 
the subjects from completing the study; and women who were pregnant or nursing.34 
Subjects were assigned 2:1 to either a treatment group in which they received 600 µg 
Cr3+ in the form of CrPic and 2 mg biotin, or a placebo group, with a study length of 90 days.  
As in the Singer et al33 study, CrPic and biotin were administered as a single capsule 
manufactured under the name Diachrome® by Nutrition 21, Inc., Purchase, NY. 
Randomization occurred via standardized computer software. The study medication was 
randomized by personnel unaffiliated with the study from Nutrition 21, Inc., who kept 
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records of the randomization schedule and blinding codes. All study site personnel were 
blinded to which subjects received treatment.34 
Both the treatment group and placebo group were balanced at study commencement 
with respect to demographics, ie, age, sex, race, weight, height, BMI and BP (p= 0.06 to 
0.53). Of the 447 randomized patients at the study beginning, 78 (17.4%) were dropped or 
lost to follow-up, and an additional 21 had significant protocol violations not originally 
accounted for. Numerical differentiation data for loss to follow-up between the treatment and 
placebo groups were not presented; however, the authors stated there was no significant 
difference in attrition rates between the treatment and placebo groups.34 
Data were collected on 348 patients considered eligible for analysis after these losses; 
226 patients were assigned to the treatment group and 122 patients were assigned to the 
placebo group. Data were recorded as mean values ± SEM (see Table 2). Treatment with 
CrPic and biotin significantly reduced HbA1c by 0.54 ± 0.15% (p= 0.0001), as compared to 
placebo reduction of 0.34 ± 0.15% (p= 0.0001); treatment vs. placebo was p= 0.03. In a 
subset of study patients whose initial HbA1c was >10.0%, a much greater reduction of 1.76 ± 
0.23% (p= 0.0001) was seen; placebo reduction in this group was 0.68 ± 0.30% (p= 0.006), 
and treatment vs. placebo in this group was p= 0.005. Fasting glucose overall was reduced by 
9.8 ± 8.5 mg/dL (p= 0.002) as compared to placebo which actually increased by 0.7 ± 5.9 
mg/dL (p= 0.84); treatment vs. placebo was p= 0.02. Fasting insulin resulted in no 
statistically significant change in either the treatment or placebo groups. Based on the 
statistical significance of these results and the lack of hypoglycemic events or serious ADRs, 
the authors of this study made recommendations for the use of CrPic and biotin supplements 
to further lower HbA1c.34 
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DISCUSSION 
 The goal of this systematic review was to explore the possibility that two OTC dietary 
supplements, CrPic and biotin, may further improve glycemic control in patients with DMT2 
as adjunct therapy to prescription OADs. Two studies were found33,34 that provide some 
evidence that these supplements may be effective. 
A single combination supplement, Diachrome®, was tested in both the Singer et al33 
and Albarracin et al34 studies. As of this writing, Diachrome® was no longer offered by 
Nutrition 21, Inc., and attempts to contact Nutrition 21, Inc. for more information on this 
supplement were unsuccessful.  Although a 2012 study found that CrPic and biotin 
supplementation decreased serum glucose and in a diabetic rat model,35 no human studies 
were found that tested both CrPic and biotin as separate supplements.  
The patients in the Singer et al33 and Albarracin et al34 studies examined in this 
review, in which the supplement  Diachrome® was used, did not experience serious ADRs or 
hypoglycemic events. This is in stark contrast to the numerous ADRs patients experience 
with the use of standard prescription OADs. For example, first-line prescription OAD 
treatment for a newly-diagnosed patient with DMT2 is either metformin or a sulfonylurea.36 
Between 20-30% of patients experience unpleasant gastrointestinal effects including nausea, 
vomiting, diarrhea and excess flatulence while using metformin.18,37,38 
Prescription OADs offer an average of 1-2% reduction in HbA1c.42,43 The Albarracin 
et al34 study demonstrated modest overall HbA1c reduction of 0.54% and a substantial 
HbA1c reduction of 1.76% in those with baseline HbA1c >10.0%; these reductions are 
similar to those seen with prescription OADs. In both the Singer et al33 and Albarracin et al34 
studies, ADRs that occurred with therapeutic doses of CrPic and biotin were not significant 
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and were not different from placebo. The lack of significant ADRs seen with CrPic and 
biotin use in both studies are promising results. Moreover, the FDA considers both CrPic and 
biotin to be generally recognized as safe (GRAS) dietary supplements, even at doses 
significantly higher than what were used in these studies.44  
Although not specifically examined in this paper, it is interesting to note that the 
triglyceride:HDL ratio significantly reduced in the treatment groups in both the Singer et al33 
study (treatment vs. placebo p= 0.0453) and the Albarracin et al34  study (treatment vs. 
placebo p= 0.05). Also, a statistically significant triglyceride level decrease was observed in 
in the treatment group in the Singer et al33 study (treatment vs. placebo p= 0.0159). Changes 
in the other lipid values measured in both studies were not statistically significant from 
placebo. 
Risk for potential bias was seen in both studies. Publication bias is a possible factor in 
both the Singer et al33 and Albarracin et al34 studies, due to the fact that funding was provided 
for both studies by Nutrition 21, Inc., maker of Diachrome®, the therapy in question. 
Referral bias may have occurred in the Singer et al33 study since it was conducted at a single 
site and gave no details pertaining to how patient selection or recruitment occurred. Selection 
bias did not appear to play a significant role in either of the studies; the patient demographic 
data were not found to be dissimilar between the treatment and placebo groups. Attrition bias 
is in question for the Singer et al33 study due to the fact that six out of the seven lost to 
follow-up were from the placebo group.   
One important flaw concerning both studies was that neither controlled for amount or 
type of prescription OADs patients were taking at the beginning of the study. Prescription 
OADs were not considered statistically significant between treatment and placebo groups in 
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the Albarracin et al34 study (p= 0.85); the Singer et al33 study did not present these values. It 
is unknown if concomitant usage of OADs had an impact on the data, whether increasing or 
decreasing glycemic control effects obtained from CrPic and biotin use. Another important 
flaw in both studies was the small patient sample size, having been n= 43 and n= 447 in the 
Singer et al33 and Albarracin et al34 studies, respectively. These patient sample sizes may not 
be adequate for the results to relevantly apply to the vast diabetic population as a whole.   
The duration of the Albarracin et al34 study (90 days) was sufficient enough to obtain 
post-treatment HbA1c results. Although the OGTT was considered the gold standard for 
measurement of glycemic control, it has largely been replaced clinically by HbA1c; HbA1c 
gives the value of blood-glucose levels over the prior 2-3 months.45-47  HbA1c was not used 
in the Singer et al33 study because the study duration was 30 days; as a consequence, plasma 
fructosamine was used post-treatment for data collection due to the fact that it will provide a 
blood-glucose value for the prior 2-3 weeks.48 Similar to HbA1c, fructosamine gives a 
reasonable estimation of blood glucose, though fructosamine measures glycated serum 
proteins, as opposed to HbA1c which measures glycated serum hemoglobin. Fructosamine 
measurement does not provide an exact correlation to HbA1c, but it can be used as a rough 
surrogate marker for HbA1c.45,46,49 
Unfortunately the studies did not use the same patient inclusion and exclusion 
criteria.  Inclusion criteria was very similar between studies; however, while the exclusion 
criteria was limited in the Singer et al33 study, it was extensive in the Albarracin et al34 study. 
This may be overlooked considering the Singer et al33 study was the first study of its kind in 
humans, and was deemed a “pilot” study by the authors. It was apparent that the Albarracin 
et al34 study was designed to further investigate the effects of CrPic and biotin based on the 
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results of the Singer et al33 study. Both studies show promise, but again are limited because 
of their origination and small patient sample sizes. 
CONCLUSION 
  The vast majority of the 20 million diagnosed diabetic adults in the U.S. have DMT2, 
which is associated with numerous physical health complications and a substantial economic 
burden. In addition to lifestyle changes, prescription OADs are beneficial in order to improve 
glycemic control, but for many the existing OADs are not sufficient. The combination of 
CrPic and biotin appear to have a modest impact on glycemic control improvement, but may 
have a larger benefit for those with an HbA1c of >10.0%. Based on the GRADE criteria used 
to evaluate the studies reviewed, the overall combined quality is low, and only a weak 
recommendation can be made for adjunct therapy of CrPic and biotin supplementation to 
improve glycemic control. However, considering the safety of CrPic and biotin, the evidence 
obtained from prior animal studies, the lack of significant ADRs and modest-to-substantial 
blood-glucose reducing effects seen in the two studies reviewed herein, it appears that CrPic 
and biotin supplementation as adjunct therapy to prescription OADs can be clinically 
justified. These results are promising, and warrant further investigation via additional 
randomized controlled studies using larger patient sample sizes, into the use of these 
seemingly benign and to some extent effective DMT2 therapies. 
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TABLE 1.  Characteristics of Reviewed Studies, GRADE profile 
  
Study Design 
Downgrade Criteria 
Quality Importance 
Limitations Indirectness Imprecision Inconsistency 
Publication 
bias likely 
Fructosamine 
Singer et al33 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious inconsistencies Bias likelyb Low Critical 
AUC glucose 
Singer et al33 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious inconsistencies Bias likelyb Low Critical 
Fasting Glucose  
Singer et al33 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious inconsistencies Bias likelyb Low Important 
Albarracin et al34 RCT 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Bias likelyb Moderate Important 
Fasting Insulin 
Singer et al33 RCT 
No serious 
limitations 
No serious 
indirectness 
Serious 
imprecisiona 
No serious inconsistencies Bias likelyb Low Important 
Albarracin et al34 RCT 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Bias likelyb Moderate Important 
HbA1c  
Albarracin et al34 RCT 
No serious 
limitations 
No serious 
indirectness 
No serious 
imprecision 
No serious inconsistencies Bias likelyb Lowc Critical 
aSinger et al33 study had a small sample size (n= 36); short study length of 30 days therefore HbA1c could not be measured 
  
bSinger et al33 study, Albarracin et al34 study: funded by the manufacturer of the chromium picolinate/biotin supplement that was tested 
  
c Albarracin et al34 study graded low for HbA1c due to the fact that it was the only study that measured this outcome 
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TABLE 2  Summary of findings 
    
Summary of Findings 
Glycemic Control 
Marker 
Study 
Number of Patients Effect 
Treatment 
(total) 
Placebo or no 
treatment 
(total) 
Improvement 
compared to 
baseline 
p- value 
p-value vs 
placebo 
Fructosamine 
Singer et al33 20 16 -23.0 mg/dL 0.0263 0.0263 
Albarracin et al34 226 122 N/A N/A N/A 
AUC glucose 
Singer et al33 20 16 
-4701.8 min • 
mg/dL 
0.0441 0.0264 
Albarracin et al34 226 122 N/A N/A N/A 
Fasting Glucose 
Singer et al33 20 16 +7.45 mg/dL 0.6597 0.0525 
Albarracin et al34 226 122 -9.8 mg/dL 0.002 0.02 
Fasting Insulin 
Singer et al33 20 16 +0.005 µU/mL 0.9957 0.7772 
Albarracin et al34 226 122 +0.5 µ U/mL 0.25 0.9 
HbA1c 
Singer et al33 20 16 N/A N/A N/A 
Albarracin et al34 226 122 -0.54% 0.0001 0.03 
 
